Tom 4, Supl. A (2024)
Artykuł redakcyjny
Opublikowany online: 2024-08-26
Wyświetlenia strony
25
Wyświetlenia/pobrania artykułu
41
Wstęp
DOI: 10.5603/hemedu.102271
Streszczenie
Brak
Referencje
- Ley TJ, Miller C, Ding Li, et al. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22): 2059–2074.
- Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12): 1345–1377.
- Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377(5): 454–464.
- Erba HP, Montesinos P, Kim HJ, et al. QuANTUM-First Study Group. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10388): 1571–1583.
- Dumas PY, Bertoli S, Bérard E, et al. Real-world outcomes of patients with refractory or relapsed -ITD acute myeloid leukemia: a Toulouse-Bordeaux DATAML registry study. Cancers (Basel). 2020; 12(8): 2044.
- Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory -mutated AML. N Engl J Med. 2019; 381(18): 1728–1740.
- Perl AE, Hosono N, Montesinos P, et al. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022; 12(5): 84.
